Search - tctmd.com

Displaying 981 - 1000 of 2279

Sort: Relevancy | Date

Presentation TCT 2023

One-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From EXPAND G4

Presenter: Ralph Stephan von Bardeleben

October 24, 2023

Presentation TCT 2023

One-Year Outcomes after Amulet or Watchman/FLX Device for Percutaneous Left Atrial Appendage Closure: a Pre-Specified Analysis of the SWISS-APERO Randomized Clinical Trial

Presenter: Roberto Galea

October 24, 2023

Presentation TCT 2023

TRILUMINATE Pivotal: Outcomes of Both Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation

Presenter: David Adams

October 24, 2023

Presentation TCT 2023

Clinician Perspectives

Presenter: Roxana Mehran

October 24, 2023

Presentation TCT 2023

Industry Perspectives

Presenter: Duane Pinto

October 24, 2023

Presentation TCT 2023

Tendyne SUMMIT Pivotal Trial Roll-In and MAC Arm Outcomes

Presenter: Jason Rogers

October 24, 2023

Presentation TCT 2023

FDA Perspectives

Presenter: Katherine Trivedi

October 24, 2023

Presentation TCT 2023

Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial

Presenter: Rebecca Hahn

October 24, 2023

Presentation TCT 2023

Overcoming the "Credibility Crisis" of Observational Data

Presenter: Robert Yeh

October 24, 2023

Presentation TCT 2023

Discussion and Closing Remarks

Presenter: Robert Yeh

October 24, 2023

Presentation TCT 2023

Lithotrispy: A novel approach to calcium fragmentation

Presenter: Stefan Verheye

October 24, 2023

Presentation TCT 2023

Technology options for patients at high thrombotic risk: Why care?

Presenter: Roxana Mehran

October 24, 2023

Presentation TCT 2023

What is the long-term potential for restoring vessel function

Presenter: IGNACIO CRUZ GONZALEZ

October 24, 2023

DynamX bioadapter- novel solution for CAD patients

Presentation TCT 2023

DynamX bioadaptor- novel solution for CAD patients

Presenter: Mirvat Alasnag

October 24, 2023

Presentation TCT 2023

Opening Remarks and Learning Objectives

Presenter: Robert Yeh

October 24, 2023

Presentation TCT 2023

ALIGN-AR Trial: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement in High Risk Patients With Symptomatic Severe Native Aortic Regurgitation

Presenter: Vinod Thourani

October 24, 2023

Presentation TCT 2023

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - WATCH TAVR Trial Results

Presenter: Samir Kapadia

October 24, 2023

Presentation TCT 2023

Four-Year Outcomes From the EVOLUT Low Risk Trial

Presenter: Michael Reardon

October 24, 2023

Presentation TCT 2023

The FDA Total lifecycle Advisory Program (FDA-TAP)

Presenter: April Marrone

October 24, 2023

Presentation TCT 2023

Understanding the New Technology Add-on Payments Program (NTAP)

Presenter: Dominic Allocco

October 24, 2023

Advertisement

One-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From EXPAND G4

One-Year Outcomes after Amulet or Watchman/FLX Device for Percutaneous Left Atrial Appendage Closure: a Pre-Specified Analysis of the SWISS-APERO Randomized Clinical Trial

TRILUMINATE Pivotal: Outcomes of Both Randomized and Single-arm Subjects with Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation

Clinician Perspectives

Industry Perspectives

Tendyne SUMMIT Pivotal Trial Roll-In and MAC Arm Outcomes

FDA Perspectives

Five-year Echocardiographic Outcomes From The PARTNER 3 Low-risk Randomized Trial

Overcoming the "Credibility Crisis" of Observational Data

Discussion and Closing Remarks

Lithotrispy: A novel approach to calcium fragmentation

Technology options for patients at high thrombotic risk: Why care?

What is the long-term potential for restoring vessel function

DynamX bioadaptor- novel solution for CAD patients

Opening Remarks and Learning Objectives

ALIGN-AR Trial: Initial Outcomes of the JenaValve Trilogy Transcatheter Aortic Valve Replacement in High Risk Patients With Symptomatic Severe Native Aortic Regurgitation

Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - WATCH TAVR Trial Results

Four-Year Outcomes From the EVOLUT Low Risk Trial

The FDA Total lifecycle Advisory Program (FDA-TAP)

Understanding the New Technology Add-on Payments Program (NTAP)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content